Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - Pharmaceutical News - Analyst Activity Noble Financial Reiterates Buy on ContraVir Pharmaceuticals (NASDAQ:CTRV) - April 23, 2017

Pharmacy News Article

 4/21/17 - Analyst Activity Noble Financial Reiterates Buy on ContraVir Pharmaceuticals (NASDAQ:CTRV)

Analyst Ratings For ContraVir Pharmaceuticals (NASDAQ:CTRV)

Today, Noble Financial reiterated its Buy rating on ContraVir Pharmaceuticals (NASDAQ:CTRV).

There are 3 buy ratings on the stock.

The current consensus rating on ContraVir Pharmaceuticals (NASDAQ:CTRV) is Buy (Score: 3.00) with a consensus target price of $4.00 per share, a potential 166.67% upside.

Some recent analyst ratings include

  • 4/21/2017-Noble Financial Reiterated Rating of Buy.
  • 6/1/2016-ING Group initiated coverage with a Positive rating.

Dividend information for ContraVir Pharmaceuticals (NASDAQ:CTRV)

.
Recent Insider Trading Activity For ContraVir Pharmaceuticals (NASDAQ:CTRV)
ContraVir Pharmaceuticals (NASDAQ:CTRV) has insider ownership of 3.30% and institutional ownership of 5.49%.

  • On 2/18/2016 James Sapirstein, CEO, bought 10,000 with an average share price of $1.00 per share and the total transaction amounting to $10,000.00. View SEC Filing
  • On 11/23/2015 James Sapirstein, CEO, bought 2,500 with an average share price of $1.64 per share and the total transaction amounting to $4,100.00. View SEC Filing
  • On 3/4/2014 John P Brancaccio, Director, bought 4,393 with an average share price of $1.49 per share and the total transaction amounting to $6,545.57. View SEC Filing

About ContraVir Pharmaceuticals (NASDAQ:CTRV)
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company's CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company's CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company's FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.

Recent Trading Activity for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Shares of ContraVir Pharmaceuticals closed the previous trading session at 1.50 down -0.11 -6.83% with 4,757,479 shares trading hands.

The post Analyst Activity Noble Financial Reiterates Buy on ContraVir Pharmaceuticals (NASDAQ:CTRV) appeared first on Market Exclusive.



© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Apr 24: A Look Inside the Top 200 Drugs
Last Chance
Apr 25: Skin Infections: Focus on Cellulitis & MRSA
Apr 26: Medical Marijuana: Examining the Science, Not the Politics
Apr 27: What's New? New Treatments for Type 2 Diabetes
Apr 30: Using Effective Communication to Reduce Medication Errors
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415